| 辅导对象 | 成都纽瑞特医疗科技股份有限公司 | | --- | --- | | 成立日期 | 2016年4月1日 | | 注册资本 | 6806. 124 万元 法定代表人 蔡继鸣 | | 注册地址 | 四川省成都市双流区西航港经济开发区空港三路 999号 | | 控 股 股东 及持股比 伊 | 宁波梅山保税港区钮特投资管理合伙企业(有限合伙),持有公司 22. 4798%的股份 | | 行业分类 | 在其他交易场 所(申请)挂 C27-医药制造业 无 牌或上市的情 况 | | 注 | 无 | 瑞财经 刘治颖 1月29日，成都纽瑞特医疗科技股份有限公司（以下简称：纽瑞特医疗）在四川证监局完 成IPO辅导备案，拟A股上市，辅导机构为国泰海通证券股份有限公司。 纽瑞特医疗成立于2016年4月，法定代表人为蔡继鸣，注册资本为6806.12万元，致力于医用同位素和放 射性药品的创新研发、生产及商业化。 公司在研多款创新产品。包括钇[90Y]炭微球注射液、核素偶联生物单抗/ 多肽等产品。主要用于诊断和 治疗肝癌、胰腺癌、淋巴癌、甲状腺癌、前列腺癌、肺癌等高发癌症。 纽瑞特医疗控股股东为宁波梅山保税港区钮特投资管理 ...

官网显示，纽瑞特医疗创始团队包括钱积惠、李茂良、蔡继鸣。目前，钱积惠、李茂良担任公司名誉董 事长，蔡继鸣担任公司董事长、总裁。 钱积惠于2016年联合创立成都纽瑞特医疗科技有限公司，自公司成立以来担任第一届、第二届董事会董 事、战略委员会主任。钱积惠毕业于哈尔滨工业大学，研究员级高级工程师。曾担任中国核动力研究设 计院院长，并曾两次赴联合国国际原子能机构任职，任副总干事长达10年。曾兼任国家核安全局专家委 员会委员、国防科工局科技委高级顾问、中核集团科技委高级顾问、清华大学核能研究院客座教授等职 务。 | 辅导对象 | 成都纽瑞特医疗科技股份有限公司 | | --- | --- | | 成立日期 | 2016年4月1日 | | 注册资本 | 6806. 124 万元 法定代表人 蔡继鸣 | | 注册地址 | 四川省成都市双流区西航港经济开发区空港三路 999号 | | 控 股 股东 及持股比 伊 | 宁波梅山保税港区钮特投资管理合伙企业(有限合伙),持有公司 22. 4798%的股份 | | 行业分类 | 在其他交易场 所(申请)挂 C27-医药制造业 无 牌或上市的情 况 | | 注 | 无 | 瑞财经 刘 ...

Economic Performance - Chengdu's GDP for 2025 is projected to be 24,763.6 billion yuan, reflecting a 5.8% increase from the previous year at constant prices [1] - Fixed asset investment in Chengdu grew by 2.2% year-on-year, outperforming national and provincial averages by 6 and 4.6 percentage points respectively [6] - The total retail sales of social consumer goods reached 11,434.1 billion yuan, marking a 5.5% increase from the previous year [1] - Foreign trade imports and exports hit a record high of 8,502.3 billion yuan [1][21] Investment and Project Development - Chengdu initiated a "100-day special action" to promote project investment, resulting in significant improvements in project initiation and quality [6][7] - In 2025, 995 key projects completed investments of 3,809.8 billion yuan, exceeding the annual plan by 12.6 percentage points [7] - The opening rate of projects reached 97.1%, an increase of 32.9 percentage points compared to before the special action [7] Industrial Development - Chengdu is implementing the "Stand Park Full Park" initiative, optimizing a park system of "3+22+N" to support industrial growth [8] - The city is focusing on 17 key industrial chains to strengthen, extend, and supplement these chains through a "chain leader + special class" approach [8] - Chengdu has established 14 billion-level parks and 26 500-million-level parks, which significantly contribute to the city's economic development [15] Innovation and Technology - Chengdu has launched several innovative projects, including the world's first 150-inch Fresnel optical screen and a new radioactive drug for pancreatic cancer [5][9][12] - The establishment of the Tianfu Jiangxi Laboratory for humanoid robots signifies Chengdu's commitment to advancing in cutting-edge technology [10] - The city has introduced policies to enhance low-altitude flight capabilities and foster a low-altitude economy [12] Economic Strategy and Governance - Chengdu's economic strategy emphasizes innovation-driven development, open leadership, and integration of science and industry [16] - The city has developed a "1+7+365" service system to support enterprises, achieving a 99.3% completion rate for business requests [16][18] - Chengdu is actively participating in national strategies such as the Belt and Road Initiative and the Chengdu-Chongqing Economic Circle [20][21]